Recent Company News

• 09:10 AM ET Jun 30, 2026
  

  Jaguar Health provides additional results of evaluation of crofelemer as adjunctive oral therapy for the treatment of Pediatric intestinal failure at ESPGHAN 2026 ($2.96, 0.00)

• 04:10 PM ET Jun 22, 2026
  

  RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

• 08:58 AM ET Jun 18, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 18-Jun

• 08:02 AM ET Jun 18, 2026
  

  RedHill Biopharma Announces Up To $19.4 Million Private Placement

• 08:03 AM ET Jun 18, 2026
  

  RedHill Biopharma announces up to $19.4M private placement at combined purchase price of $0.70 per ADS and accompanying warrants ($0.79, 0.00)

• 07:07 AM ET Jun 09, 2026
  

  RedHill'announced that the FDA has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB) ($1.02, 0.00)

• 07:01 AM ET Jun 09, 2026
  

  RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation